SRR8613805
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.280
- XENOBIOTIC_METABOLISM+0.280
- ADIPOGENESIS+0.230
- BILE_ACID_METABOLISM+0.230
- HEDGEHOG_SIGNALING+0.220
- ANDROGEN_RESPONSE+0.190
- PEROXISOME+0.170
- PI3K_AKT_MTOR_SIGNALING+0.130
- ESTROGEN_RESPONSE_EARLY+0.090
- APICAL_SURFACE+0.080
Top 10 suppressed
- E2F_TARGETS-0.490
- G2M_CHECKPOINT-0.420
- MYC_TARGETS_V2-0.420
- MYC_TARGETS_V1-0.400
- ANGIOGENESIS-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- INTERFERON_ALPHA_RESPONSE-0.310
- INFLAMMATORY_RESPONSE-0.240
- IL6_JAK_STAT3_SIGNALING-0.210
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1205 | — | — | 0.825 |
| 2 | SRR8518242 | — | F | 0.820 |
| 3 | SRR8613744 | — | F | 0.794 |
| 4 | SRR8518290 | — | F | 0.791 |
| 5 | BS_13CGKADW | pilocytic astrocytoma | — | 0.790 |
| 6 | SRR8518452 | — | A | 0.783 |
| 7 | R142 | — | — | 0.781 |
| 8 | BS_CGB2WS2A | pilocytic astrocytoma | — | 0.775 |
| 9 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.774 |
| 10 | BS_VMMJYN8Z | Ganglioglioma | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |